Search Results 971-980 of 21672 for Inhibition

1. Precision medicine for breast cancer - Care at Mayo Clinic

   ... inhibitors, fulvestrant and tamoxifen. Nationally recognized expertise. Mayo Clinic was chosen to serve as the nation's national Precision Medicine ...

2. Schwannomatosis Clinical Trials - Mayo Clinic Research

   A Study Using Targeted Inhibitors to Treat Specific Tumor Mutations in Patients with Meningiomas ... Vismodegib and FAK inhibitor GSK2256098 may stop the growth ...

3. A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma - Mayo Clinic

   Patients must not have had progressive disease while on therapy with vinblastine or a MEK inhibitor; ... inhibitors of CYP3A4 within 7 days prior to study ...

4. Lewy body dementia - Diagnosis and treatment - Mayo Clinic

   Cholinesterase inhibitors. These Alzheimer's disease medicines increase levels of chemical messengers in the brain, known as neurotransmitters. These ...

5. Allopurinol (oral route) - Side effects & dosage - Mayo Clinic

   Allopurinol is a xanthine oxidase inhibitor that works by decreasing the uric acid produced by the body. This medicine is available only with your doctor's ...

6. Non-cardiac Chest Pain Treatment with Virtual Reality - Mayo Clinic

   Participation eligibility · Initiation of a proton pump inhibitor (PPI) within 8 weeks. · Major concomitant illness. · Current drug or alcohol use that that would ...

7. Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease - Mayo Clinic

   ... inhibitors including but not limited to antiretrovirals (protease inhibitors) (e.g.Indinavir, Nelfinavir, Ritonavir, Saquinavir); Imidazole and Triazole ...

8. Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma - Mayo Clinic

   All CYP2C8 inhibitors, inducers, and substrates should be discontinued >= 7 days prior to registration; systemic treatment with CYP2C8 inhibitors ...

9. A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors - Mayo Clinic

   Concurrent administration of strong cytochrome P450 (CYP) 3A4 inhibitors and inducers, and multidrug resistance mutation 1 inhibitors. ... Proton pump inhibitor ...

10. A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma - Mayo Clinic

    proteasome inhibitor (PI) and immunomodulatory therapy (IMiD), and lenalidomide refractory per International Myeloma Working Group (IMWG) guidelines